Home Cart Sign in  
Chemical Structure| 1462249-75-7 Chemical Structure| 1462249-75-7

Structure of PFK158
CAS No.: 1462249-75-7

Chemical Structure| 1462249-75-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PFK158

CAS No. :1462249-75-7
Formula : C18H11F3N2O
M.W : 328.29
SMILES Code : O=C(C1=CC=NC=C1)/C=C/C2=NC3=CC(C(F)(F)F)=CC=C3C=C2
MDL No. :MFCD28386154
InChI Key :IAJOMYABKVAZCN-AATRIKPKSA-N
Pubchem ID :71730058

Safety of PFK158

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Acute myeloid leukemia cells 0.9 μM 96 hours Evaluate the inhibitory effect of PFK158 combined with meclizine on AML cells, showing synergistic inhibition J Hepatol. 2020 Apr;72(4):746-760.
HuH7 cells 2 or 5 μM 24 and 48 hrs Evaluate the inhibitory effect of PFK158 combined with meclizine on the growth of liver cancer cells, showing synergistic inhibition J Hepatol. 2020 Apr;72(4):746-760.
HepG2 cells 2 or 5 μM 24 and 48 hrs Evaluate the inhibitory effect of PFK158 combined with meclizine on the growth of liver cancer cells, showing synergistic inhibition J Hepatol. 2020 Apr;72(4):746-760.
DMS53 cells 0, 2.5, 5, 10 μM 24 hours Inhibition of glycolysis, proliferation, spheroid formation, and the expression of cancer stem cell markers CD133, Aldh1, CD44, Sox2, and ABCG2 Oncogene. 2022 Aug;41(33):4003-4017.
H1876 cells 0, 2.5, 5, 10 μM 24 hours Inhibition of glycolysis, proliferation, spheroid formation, and the expression of cancer stem cell markers CD133, Aldh1, CD44, Sox2, and ABCG2 Oncogene. 2022 Aug;41(33):4003-4017.
H1882 cells 0, 2.5, 5, 10 μM 24 hours Inhibition of glycolysis, proliferation, spheroid formation, and the expression of cancer stem cell markers CD133, Aldh1, CD44, Sox2, and ABCG2 Oncogene. 2022 Aug;41(33):4003-4017.
H1048 cells 0, 2.5, 5, 10 μM 24 hours Inhibition of glycolysis, proliferation, spheroid formation, and the expression of cancer stem cell markers CD133, Aldh1, CD44, Sox2, and ABCG2 Oncogene. 2022 Aug;41(33):4003-4017.
Patient-derived ascites cells 3-5µM 24 hours To evaluate the effect of PFK158 on cell viability, results showed that PFK158 treatment reduced cell viability and restored primary cilia formation J Exp Clin Cancer Res. 2021 Jun 3;40(1):182.
OVCAR5 10µM 24 hours To evaluate the effect of PFK158 on primary cilia formation, results showed that PFK158 treatment significantly restored primary cilia formation J Exp Clin Cancer Res. 2021 Jun 3;40(1):182.
OVCAR8 10µM 24 hours To evaluate the effect of PFK158 on primary cilia formation, results showed that PFK158 treatment significantly restored primary cilia formation J Exp Clin Cancer Res. 2021 Jun 3;40(1):182.
EMMeso 0-30μM 24 and 48 hours PFK158 treatment inhibited MPM cell viability with IC50 values ranging from 3 to 12μM Cell Death Dis. 2019 Sep 27;10(10):725.
NCI-H28 0-30μM 24 and 48 hours PFK158 treatment inhibited MPM cell viability with IC50 values ranging from 3 to 12μM Cell Death Dis. 2019 Sep 27;10(10):725.
OVCAR8 cells 5 µM 48 hours To evaluate the effect of PFK158 on PARPi resistance, results showed that PFK158 inhibited PFKFB3 activity and enhanced PARPi sensitivity. Cell Commun Signal. 2025 Jan 25;23(1):48.
SKOV3 cells 5 µM 48 hours To evaluate the effect of PFK158 on PARPi resistance, results showed that PFK158 inhibited PFKFB3 activity and enhanced PARPi sensitivity. Cell Commun Signal. 2025 Jan 25;23(1):48.
ARK-2 0-20 μM 24-72 hours Inhibited cell proliferation, reduced glucose uptake, ATP production, and lactate dehydrogenase activity Oncogene. 2021 Feb;40(8):1409-1424.
HEC-1B 0-20 μM 24-72 hours Inhibited cell proliferation, reduced glucose uptake, ATP production, and lactate dehydrogenase activity Oncogene. 2021 Feb;40(8):1409-1424.
HeyA8MDR 5μM 30 minutes To evaluate the effect of PFK158 on glucose uptake, results showed that PFK158 treatment significantly decreased glucose uptake Int J Cancer. 2019 Jan 1;144(1):178-189.
HeyA8 5μM 30 minutes To evaluate the effect of PFK158 on glucose uptake, results showed that PFK158 treatment significantly decreased glucose uptake Int J Cancer. 2019 Jan 1;144(1):178-189.
C13 5μM 30 minutes To evaluate the effect of PFK158 on glucose uptake, results showed that PFK158 treatment significantly decreased glucose uptake Int J Cancer. 2019 Jan 1;144(1):178-189.
OV2008 5μM 30 minutes To evaluate the effect of PFK158 on glucose uptake, results showed that PFK158 treatment significantly decreased glucose uptake Int J Cancer. 2019 Jan 1;144(1):178-189.
EMMeso 5 µM 24 hours PFK158 treatment significantly increased p27 levels in EMMeso cells. Br J Cancer. 2022 Oct;127(7):1352-1364.
NCI-H2052 2.5 µM 24 hours PFK158 significantly decreased SOX2 and CD133 transcript levels in H2052 cells. Br J Cancer. 2022 Oct;127(7):1352-1364.
NCI-H28 2.5 µM 24 hours PFK158 significantly decreased SOX2, CD133 and CD44 transcript levels in H28 cells. Br J Cancer. 2022 Oct;127(7):1352-1364.
DMS79 2.5 μM 72 hours To evaluate the effect of PFK158 on ATP production, glucose uptake, and lactate secretion in MYC-low SCLC cell lines. Results showed that PFK158 had minimal effect on ATP production, glucose uptake, and lactate. Cancer Metab. 2021 Sep 23;9(1):33.
H446 2.5 μM 72 hours To evaluate the effect of PFK158 on ATP production, glucose uptake, and lactate secretion in MYC-high SCLC cell lines. Results showed that PFK158 significantly attenuated glucose uptake, ATP production, and lactate. Cancer Metab. 2021 Sep 23;9(1):33.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID-NSG mice H1048 CSC xenograft model Intraperitoneally (ip) 25 mg/kg Twice a week for 3 weeks PFK158 treatment and PFKFB3 knockdown significantly reduced tumor growth and weight with reduced expression of cancer stem cell markers, ABCG2, and YAP/TAZ Oncogene. 2022 Aug;41(33):4003-4017.
NOG mice Human hepatocarcinoma cell line xenotransplantation model Oral 25 mg/kg Once daily for two weeks Evaluate the inhibitory effect of PFK158 combined with meclizine on liver cancer growth, showing significant reduction in tumor burden J Hepatol. 2020 Apr;72(4):746-760.
Female athymic nude mice EMMeso xenograft model Subcutaneous injection 30 mg/kg Twice a week for 2 weeks PFK158 alone or in combination with carboplatin significantly inhibited tumor growth Cell Death Dis. 2019 Sep 27;10(10):725.
BALB/c nude mice SKOV3 xenograft models Intraperitoneally 35 mg/kg Twice weekly for 28 days To evaluate the in vivo efficacy of PFK158 combined with PARPi, results showed that the combination significantly inhibited tumor growth and increased DNA damage. Cell Commun Signal. 2025 Jan 25;23(1):48.
Nude mice HEC-1B and ARK-2 xenograft models Intraperitoneal injection 35 mg/kg Twice weekly for 14 days Significantly inhibited tumor growth, reduced tumor volume and weight, and enhanced chemosensitivity Oncogene. 2021 Feb;40(8):1409-1424.
Female athymic nude mice Highly metastatic PTX-resistant ovarian mouse model Intraperitoneal injection 25 mg/kg PFK158 every 3rd day, CBPt every 3rd day, PTX every 5th day, for 28 days To evaluate the effect of PFK158 alone or in combination with CBPt/PTX on tumor growth and ascites, results showed that the combination treatment significantly reduced tumor weight and ascites Int J Cancer. 2019 Jan 1;144(1):178-189.
Female athymic nude mice MPM xenograft model 30 mg/kg Twice a week for 2 weeks PFK158 significantly reduced tumour burden, tumour weight and tumour volume in TIC-mediated MPM xenografts. Br J Cancer. 2022 Oct;127(7):1352-1364.
Mice Apoe−/− mice Intraperitoneal injection 2 mg/kg 3 times per week for 5 weeks To evaluate the effect of PFK158 on plaque stability, results showed that PFK158 improved plaque stability. Br J Pharmacol. 2022 Nov;179(21):4974-4991.
Nude mice H446 xenograft model Intraperitoneal injection 25 mg/kg Every 2 days for a total of six treatments To evaluate the effect of PFK158 on tumor growth in MYC-high SCLC xenograft models. Results showed that PFK158 significantly delayed tumor growth. Cancer Metab. 2021 Sep 23;9(1):33.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.05mL

0.61mL

0.30mL

15.23mL

3.05mL

1.52mL

30.46mL

6.09mL

3.05mL

References

 

Historical Records

Categories